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Supplemental Figures 
 
Figure S1. Polyfunctional CD4+ and CD8+ T-cell subpopulations defined by single-cell 
analysis. These functional subsets were determined by principal component analysis, within 
CD4+ and CD8+ product T-cell subsets. The representation is based on clustering utilizing 
cytokines produced by individual cells as a 2-dimensional representation of objects in 
multidimensional space. The major polyfunctional subsets defined by similarity in the cytokines 
produced are represented as clusters, with individual dots corresponding to cells. The intensity 
of dots reflects the cytokine production level. The polyfunctionality of the T-cell population not 
stimulated with CD19+ cells is overlaid (blue color, NGFR) as a control. The major cytokines 
that are most commonly represented within each major population, CD4 and CD8 T cells, 
respectively, have been used to organize this principal component analysis (indicated on x and 
y axis), and the cytokines defining each cluster are indicated. The frequency of polyfunctional 
cells, comprising only about 20%-25% of all immunologically relevant cells, is also represented. 
IFN, interferon; IL, interleukin; MIP, macrophage inflammatory protein; NGFR, nerve growth 
factor receptor; TNF-a, tumor necrosis factor-a. 
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Figure S2. Association between PSI in conjunction with CAR T-cell levels in blood or day 
0 IL-15 levels in serum and OR. CAR T-cell levels in blood were measured by qPCR. A 
composite index integrating PSI and CAR T-cell expansion in vivo was developed as detailed in 
Methods and associated with response outcome (R = response; N = no response). Whole-
product PSI, CD4+ PSI, and IL-17A PSI indexes were all evaluated in conjunction with CAR 
peak levels. The 2 metrics were combined into a joint metric to test their association with a 
patient outcome. The metrics were added to each other after first standardizing each of them to 
have unit variance. This standardization was achieved by dividing the metric by their respective 
standard deviation to bring them to a common magnitude/scale. Joint PSI and day 0 IL-15 level 
metrics were calculated similarly. Statistical values were computed using the Mann Whitney U 
test. P values were not adjusted for multiplicity. CAR, chimeric antigen receptor; OR, objective 
response; PSI, polyfunctionality strength index; qPCR, quantitative polymerase chain reaction. 
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Figure S3. PSI does not associate with CAR T-cell levels in blood. CAR T-cell levels in 
blood were measured by qPCR and correlated with PSI or clinical outcome (OR, grade 3+ NT or 
CRS). Whole-product PSI, CD4+ PSI, and IL-17A PSI are displayed. Statistical analysis was 
performed using Spearman’s correlation and Mann Whitney U tests. CRS, cytokine release 
syndrome; NT, neurologic toxicity. 
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Figure S4. Association between PSI in conjunction with CAR T-cell levels in blood, and 
grade 3+ NT; A) or CRS; B). CAR T-cell levels in blood were measured by qPCR and 
correlated with grade 3+ AEs. A composite index integrating PSI and CAR T-cell expansion in 
vivo was developed as detailed in Methods and associated with NT or CRS, respectively. 
Whole-product PSI, CD4+ PSI, and IL-17A PSI indexes were all evaluated in conjunction with 
CAR peak levels. The 2 metrics were combined into a joint metric to test their association with a 
patient outcome. The metrics were added to each other after first standardizing each of them to 
have unit variance. This standardization was achieved by dividing the metric by their respective 
standard deviation to bring them to a common magnitude/scale. Statistical values were 
computed using the Mann Whitney U test. P values were not adjusted for multiplicity. CRS, 
cytokine release syndrome; NT, neurologic toxicity. 
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Figure S5. Association between PSI in conjunction with pretreatment IL-15 levels in 
blood, and grade 3+ NT (A) or CRS (B). IL-15 levels in blood were measured by ELISA and 
correlated with grade 3+ AEs. A composite index integrating PSI and IL-15 levels was 
developed as detailed in Methods and associated with grade 3+ NT or CRS, respectively. 
Whole-product PSI, CD4+ PSI, and IL-17A PSI were all evaluated in conjunction with IL-15 
levels. Statistical values were computed using the Mann Whitney U test. P values were not 
adjusted for multiplicity. ELISA, enzyme-linked immunosorbent assay. CRS, cytokine release 
syndrome; NT, neurologic toxicity. 
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Table S1. Product gene expression correlations with PSI. The table shows associations 
between PSI and ratio of CAR gene expression /T-cell–related molecules, all measured 
quantitatively by NanoString. CAR gene expression was measured utilizing probes for CD28 
CD3zeta junction and scFv, respectively. T-cell–related mRNA was measured utilizing probes 
for CD3D, CD3E, CD3G, and CD6. CD3E was also measured at protein level using anti-CD3 
mAb OKT3, by NanoString. PSI was also analyzed against T-cell molecules alone. The analysis 
was done by linear regression.  mAb, monoclonal antibody; * P < .05. ** P < .005.  
 
PSI versus Alone 
Ratio versus 
CD28_CD3z  
Ratio versus 
scFv 
CD3D 0.9925 0.0077* 0.0141* 
CD3E 0.7122 0.0029** 0.0052* 
CD3G 0.7051 0.0096* 0.0141* 
CD6 0.7502 0.0019** 0.0075* 
CD3E (OKT3) 0.8849 0.0043** 0.0032** 
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Table S2. Associations between product IL-17 PSI and product T-cell characteristics. 
Association between major product characteristics and IL-17A PSI was performed by linear 
regression. CD4:CD8 ratio was calculated based on flow cytometry measurements; % T-helper 
and % Th17 cells were measured based on epigenetic analysis as described in Methods; IL-
17A and IL-6 in co-culture of product and target cells were measured by ELISA; and IL-17A PSI 
was computed as described in Methods. * P < .05. ** P < .005. *** P < .0005. 
 
Product characteristics PSI IL-17A PSI 
CD4:CD8 ratio 0.2008 0.0008** 
% T Helper (epigenetic) 0.7074 0.0038** 
% Th17 (epigenetic) 0.7407 < 0.0001*** 
IL-17A in co-culture 0.3129 <0.0001*** 
IL-6 in co-culture  0.0864 0.0006** 
 
